Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 280, Issue 5 49-5, 2001, Pages

  Jia, Dong Mei ^a   Fukumitsu, Ken Ichiro ^a   Tabaru, Akinari ^a   Akiyama, Toshiharu ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cholecystokinin A; Glucose metabolism; Insulin; Leptin; Otsuka Long Evans Tokushima fatty; Peroxisome proliferator activated receptor

Indexed keywords

CHOLECYSTOKININ A RECEPTOR; DNA; FATTY ACID; GLUCOSE; INSULIN; PANCREAS ENZYME; PROTEIN; TROGLITAZONE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; FIBROSIS; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGAN GROWTH; ORGAN WEIGHT; PANCREAS; PRIORITY JOURNAL;

EID: 0343831908     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.2001.280.5.r1332     Document Type: Article

References (66)

1. Akiyama T, Jia DM, Shirohara H, Hirohata Y, and Otsuki M. Cholecystokinin (CCK) induces leptin resistance (Abstract). Gastroenterology 118: A68-A69, 2000.
2. Bondar RJ and Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem 20: 586-590, 1974.
3. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, and Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23: 57-63, 2000.
4. Catt KJ, Harwood JP, Aguilera G, and Dufau ML. Hormonal regulation of peptide receptors and target cell responses. Nature 280: 109-116, 1979.
5. Ceska M, Birath K, and Brown B. A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Clin Chim Acta 26: 437-444, 1968.
6. Chey WY, Shay H, and Shuman CR. External pancreatic secretion in diabetes mellitus. Ann Intern Med 59: 812-821, 1963.
7. Davoren PR. The isolation of insulin from a single cat pancreas. Biochim Biophys Acta 63: 150-153, 1962.
8. Dawra R, Saluja A, Lerch MM, Saluja M, Logsdon C, and Steer M. Stimulation of pancreatic growth by cholecystokinin is mediated by high affinity receptors on rat pancreatic acinar cells. Biochem Biophys Res Commun 193: 814-820, 1993.
9. Erlanger BE, Kokowasky N, and Cohen W. The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys 95: 271-278, 1961.
10. Folsch UR, Winckler K, and Wormsley KG. Influence of repeated administration of cholecystokinin and secretin on the pancreas of the rat. Scand J Gastroenterol 13: 663-671, 1978.
11. Fujita T. Insulo-acinar portal system in the horse pancreas. Arch Histol Jap 35: 161-171, 1973.
12. Funakoshi A, Miyasaka K, Jimi A, Kawanai T, Takata Y, and Kono A. Little or no expression of the cholecystokinin-A receptor gene in the pancreas of diabetic rats (Otsuka Long-Evans Tokushima Fatty-OLETF rats). Biochem Biophys Res Commun 199: 482-488, 1994.
13. Gavin JR, Roth J Jr, Neville DM, Meyts P, and Buell DN. Insulin-dependent regulation of insulin receptor concentration: a direct demonstration in cell culture. Proc Natl Acad Sci USA 71: 84-88, 1974.
14. Goke B, Printz H, Koop I, Rausch U, Richter G, Arnold R, and Adler G. Endogenous CCK release and pancreatic growth in rats after feeding a protease inhibitor (camostat). Pancreas 1: 509-515, 1986.
15. Green GM, Levan VH, and Liddle RA. Plasma cholecystokinin and pancreatic growth during adaptation to dietary protein. Am J Physiol Gastrointest Liver Physiol 251: G70-G74, 1986.
16. Groger G and Layer P. Exocrine pancreatic function in diabetes mellitus. Eur J Gastroenterol Hepatol 7: 740-746, 1995.
17. Hellman B, Wallgren A, and Petersson B. Cytological characteristics of the exocrine pancreatic cells with regard to their position to the islets of Langerhans. Acta Endocrinol 39: 465-473, 1962.
18. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, and Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14: 1083-1086, 1991.
19. Jiang C, Ting AT, and Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86, 1998.
20. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, and Natori T. Spontaneous long term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 4: 1422-1428, 1992.
21. Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haoder W, Schmitz F, Bonner-Weir S, Kanarek R, and Beinborn M. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 103: 383-391, 1999.
22. Korc M, Iwamoto Y, Sankaran H, Williams JA, and Goldfine ID. Insulin action in pancreatic acini from streptozotocin-treated rats. I. Stimulation of protein synthesis. Am J Physiol Gastrointest Liver Physiol 240: G56-G62, 1981.
23. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, and Lettis S, and Stewart-Long P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709, 1996.
24. Labarca C and Paigen K. A simple, rapid and sensitive DNA assay procedure. Anal Biochem 102: 344-352, 1980.
25. Lacourse KA, Swanberg LJ, Gillespie PJ, Rehfeld JF, Saunders TL, and Samuelson LC. Pancreatic function in CCK-deficient mice: adaptation to dietary protein does not require CCK. Am J Physiol Gastrointest Liver Physiol 276: G1302-G1309, 1999.
26. Lammers R, Gray A, Schlessinger J, and Ullrich A. Differential signaling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 8: 1369-1375, 1989.
27. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, and Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J 12: 57-65, 1998.
28. Logsdon CD. Stimulation of pancreatic acinar cell growth by CCK, epidermal growth factor, and insulin in vitro. Am J Physiol Gastrointest Liver Physiol 251: G487-G494, 1986.
29. Lowry OH, Rosenrough NJ, Farr AL, and Randall RJ. Protein measurement with Folin-phenol reagent. J Biol Chem 193: 265-275, 1951.
30. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, and Gentilini P. Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119: 466-478, 2000.
31. Matarese G. Leptin and the immune system: how nutritional status influences the immune response. Eur Cytokine Netw 11: 7-14, 2000.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
33. Miyasaka K, Ohta M, Kanai S, Sato Y, Masucla M, and Funakoshi A. Role of cholecystokinin (CCK)-A receptor for pancreatic growth after weaning: a study in a new rat model without gene expression of the CCK-A receptor. Pancreas 12: 351-356, 1996.
34. Morgan CR and Lazarow AL. Immunoassay of insulin: two antibody system. Diabetes 12: 115-126, 1963.
35. Morisset J, Guan D, Jurkowska G, Rivard N, and Green GM. Endogenous cholecystokinin, the major factor responsible for dietary protein-induced pancreatic growth. Pancreas 7: 522-529, 1992.
36. Mossner J, Logsdon CD, Williams JA, and Goldfine ID. Insulin, via its own receptor, regulates growth and amylase synthesis in pancreatic acinar AR42J cells. Diabetes 34: 891-897, 1985.
37. Nakamura H, Kihara Y, Tashiro M, Kanagawa K, Shirohara H, Yamamoto M, Yosikawa H, Fukumitsu K-I, Hirohata Y, and Otsuki M. Expression and the CCK-A receptor-mediated biological functions in Otsuka Long-Evans Tokushima fatty (OLETF) rats. J Gastroenterol 33: 702-709, 1998.
38. Nakano S, Tachibana I, and Otsuki M. Effects of cholecystokinin receptor antagonist loxiglumide on rat exocrine pancreas. Pancreas 9: 425-433, 1994.
39. Niederau C, Liddle RA, Williams JA, and Grendell JH. Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice. Gut 28: 63-69, 1987.
40. Niederau C, Luthen R, Niederau M, Strohmeyer G, Ferrell LD, and Grendel JH. Effect of long-term stimulation and blockade on pancreatic and intestinal growth, morphology, and function. Digestion 46, Suppl 2: S217-S225, 1990.
41. Niimi M, Sato M, Yokote R, Tada S, and Takahara J. Effects of central and peripheral injection of leptin on food intake and on brain Fos expression in the Otsuka Long-Evans Tokushima Fatty rat with hyperleptinaemia. J Neuroendocrinol 11: 605-611, 1999.
42. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193, 1994.
43. Ogawa J, Takahashi S, Fujiwara T, Fukushige J, Hosokawa T, Izumi T, Kurakata S, and Horikoshi H. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Life Sci 65: 1287-1296, 1999.
44. Ohashi N, Isaji S, Kawaharada Y, Mizumoto R, Hibasami H, and Nakashima K. Effect of insulin treatment on the regeneration of the remnant pancreas after major pancreatectomy in dogs. Int J Pancreatol 9: 165-710, 1991.
45. Ohlsson B, Jansen C, Rehfeld JF, Sternby B, Ihse I, and Axelson J. Biliodigestive shunt evokes hyperCCKemia and trophic effects in the rat pancreas, but not in the liver or gastrointestinal tract. Pancreas 14: 255-261, 1997.
46. Okabayashi Y, Ohki A, Sakamoto C, and Otsuki M. Relationship between the severity of diabetes mellitus and pancreatic exocrine dysfunction in rats. Diabetes Res Clin Pract 1: 21-30, 1985.
47. Okabayashi Y, Otsuki M, Ohki A, Suehiro I, and Baba S. Effect of diabetes mellitus on pancreatic exocrine secretion from isolated perfused pancreas in rats. Dig Dis Sci 33: 711-717, 1988.
48. Otsuki M, Akiyama A, Shirohara H, Nakano S, Furumi K, and Tachibana I. Loss of sensitivity to cholecystokinin stimulation of isolated pancreatic acini from genetically diabetic rats. Am J Physiol Endocrinol Metab 268: E531-E536, 1995.
49. Otsuki M, Fujii M, Nakamura T, Tani S, and Okabayashi Y. Chronic oral administration of synthetic trypsin inhibitor camostate reduces amylase release from isolated rat pancreatic acini. Int J Pancreatol 18: 135-143, 1995.
50. Otsuki M, Ohki A, Okabayashi Y, Suehiro I, and Baba S. Effect of synthetic protease inhibitor camostate on pancreatic exocrine function in rats. Pancreas 2: 164-169, 1987.
51. Otsuki M and Williams JA. Effect of diabetes mellitus on the regulation of enzyme secretion by isolated rat pancreatic acini. J Clin Invest 70: 148-156, 1982.
52. Otsuki M and Williams JA. Amylase secretion by isolated pancreatic acini after chronic cholecystokinin treatment in vivo. Am J Physiol Gastrointest Liver Physiol 244: G683-G688, 1983.
53. Povoski SP, Zhou W, Longnecker DS, Jensen RT, Mantey SA, and Bell RH. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors. Gastroenterology 107: 1135-1146, 1994.
54. Ricote M, Li AC, Willson TM, Kelly CJ, and Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82, 1998.
55. Rivard N, Guan D, Maouyo D, Grondin G, Berube FL, and Morisset J. Endogenous cholecystokinin release responsible for pancreatic growth observed after pancreatic juice diversion. Endocrinology 129: 2867-2874, 1991.
56. Rosenfeld RG, Hintz RL, and Dollar L. Insulin-induced loss of insulin-like growth factor-1 receptors on IM-9 lymphocytes. Diabetes 31: 375-381, 1982.
57. Sakamoto C, Otsuki M, Ohki A, Kazumi T, Yamasaki T, Yuu H, Maeda M, Yoshino G, and Baba S. Exocrine and endocrine secretion from isolated perfused rat pancreas with islet cell tumors induced by streptozotocin and nicotinamide. Dig Dis Sci 29: 443-447, 1984.
58. Sankaran H, Iwamoto Y, Korc M, Williams JA, and Goldfine ID. Insulin action in pancreatic acini from streptozotocin-treated rats. II. Binding of 1251-insulin to receptors. Am J Physiol Gastrointest Liver Physiol 240: G63-G68, 1981.
59. Shima K, Shi K, Mizuno A, Sano T, Ishida K, and Noma Y. Exercise training has a long-lasting effect on prevention of non-insulin-dependent diabetes mellitus in Otsuka-Long-Evans-Tkushima fatty rats. Metabolism 45: 475-480, 1996.
60. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidine receptor. Diabetes 47: 507-514, 1998.
61. Stuber E, Alves F, Hocker M, and Folsch UR. Putrescine uptake in rat pancreatic acini: effect of secretagogues and growth factors. Pancreas 8: 433-439, 1993.
62. Tachibana I, Akiyama T, Kanagawa K, Shirohara H, Furumi K, Watanabe N, and Otsuki M. Defect in pancreatic exocrine and endocrine response to CCK in genetically diabetic OLETF rats. Am J Physiol Gastrointest Liver Physiol 270: G730-G737, 1996.
63. Whitaker JP. A rapid and specific method for the determination of pancreatic lipase in serum and urine. Clin Chim Acta 44: 133-138, 1973.
64. Wisner JR, McLaughlin RE, Rich KA, Ozawa S, and Renner IG. Effect of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rat pancreas. Gastroenterology 91: 1002-1006, 1986.
65. Yamamoto M, Jia DM, Fukumitsu K-I, Imoto I, Kihara Y, Hirohata Y, and Otsuki M. Metabolic abnormalities in genetically obese and diabetic Otsuka Long-Evans Tokushima Fatty rat can be prevented and reversed by a glucosidase inhibitor. Metabolism 48: 347-354, 1999.
66. Yang SQ, Lin HZ, Lane MD, Clemens M, and Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94: 2557-2562, 1997.